Clinical Trials

Accrual Status
Limit to SWOG Trials

1027 Results

    View
    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S1900K

    A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
    Status Notes
    S1900K will open to accrual December 18, 2023, effective 3:00 p.m. EST.
    Research Committee(s)
    LungMAP
    Activated
    12-18-2023
    ClinicalTrials.gov Registry Number
    NCT06031688
    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S2213

    A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
    Status Notes
    S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.
    Research Committee(s)
    Myeloma
    Activated
    12-01-2023
    ClinicalTrials.gov Registry Number
    06022939
    Open
    Phase
    Accrual
    1%
    SWOG Clinical Trial Number
    S2206

    A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
    Status Notes
    This study is open to patient accrual effective 10/30/23.
    Research Committee(s)
    Breast Cancer
    Symptom Control and Quality of Life
    Activated
    10-30-2023
    ClinicalTrials.gov Registry Number
    06058377
    Open
    Phase
    Accrual
    2%
    SWOG Clinical Trial Number
    S2210

    S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
    Status Notes
    Active as of 08/14/2023, 12 PM PST.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    08-14-2023
    ClinicalTrials.gov Registry Number
    NCT05806515
    Open
    Phase
    Accrual
    5%
    SWOG Clinical Trial Number
    S2212

    TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
    Status Notes
    This study is active in SWOG as of July 21, 2023.
    Research Committee(s)
    Breast Cancer
    Activated
    07-21-2023
    ClinicalTrials.gov Registry Number
    NCT05929768
    Open
    Phase
    Accrual
    5%
    SWOG Clinical Trial Number
    S2207

    Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
    Status Notes
    S2207 will open to accrual June 30, 2023, effective 3:00 p.m. EST.
    Research Committee(s)
    Lymphoma
    Activated
    06-30-2023
    ClinicalTrials.gov Registry Number
    05890352
    Open
    Phase
    Accrual
    4%
    SWOG Clinical Trial Number
    S2209

    A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
    Status Notes
    S2209 is open to patient accrual May 30, 2023, effective 12:00 p.m. Pacific Time.
    Research Committee(s)
    Myeloma
    Activated
    05-30-2023
    ClinicalTrials.gov Registry Number
    05561387
    Open
    Phase
    Accrual
    17%
    SWOG Clinical Trial Number
    S1900G

    A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
    Status Notes
    S1900G will open to accrual April 3, 2023, effective 3:00 p.m. EST.
    Research Committee(s)
    LungMAP
    Activated
    04-03-2023
    ClinicalTrials.gov Registry Number
    05642572
    Open
    Phase
    Accrual
    16%
    SWOG Clinical Trial Number
    S2205

    ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy
    Status Notes
    This study is open to patient accrual effective 3/16/23 at 12 p.m. Pacific Time.
    Research Committee(s)
    Symptom Control and Quality of Life
    Activated
    03-16-2023
    ClinicalTrials.gov Registry Number
    05642611
    Open
    Phase
    Accrual
    64%
    SWOG Clinical Trial Number
    S2302

    PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
    Status Notes
    March 6, 2023: S2302 is open to accrual.

    SWOG has partnered with Matthews Media Group (MMG) to help us increase and diversify enrollment to this trial. They may contact your site directly to offer support or ask about potential barriers.
    Research Committee(s)
    Lung Cancer
    Activated
    03-06-2023
    ClinicalTrials.gov Registry Number
    05633602
    Open
    Phase
    Accrual
    3%
    SWOG Clinical Trial Number
    EAY191-S3

    Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Patients with AKT-Altered Advanced Non-Breast Solid Tumors
    Status Notes
    This study is open to participant enrollment effective 12pm PT on 3/6/2023.
    Research Committee(s)
    comboMATCH
    Immunomolecular Therapeutics
    Activated
    03-06-2023
    ClinicalTrials.gov Registry Number
    05554380
    Open
    Phase
    Accrual
    10%
    SWOG Clinical Trial Number
    S2114

    A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
    Status Notes
    Activated: Effective Thursday, February 23, 2023 at 12:00 PM Pacific Time
    Research Committee(s)
    Lymphoma
    Activated
    02-23-2023
    ClinicalTrials.gov Registry Number
    05633615
    Open
    Phase
    Accrual
    51%
    SWOG Clinical Trial Number
    S2010

    A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
    Status Notes
    This study is open to participant accrual, effective January 17, 2023, at 12:00 p.m. Pacific Time.
    Research Committee(s)
    Symptom Control and Quality of Life
    Activated
    01-17-2023
    Open
    Phase
    Accrual
    15%
    SWOG Clinical Trial Number
    S2101

    Biomarker Stratified CaboZantinib and NivOlumab (BiCaZO) - A phase II study of combining cabozantinib and nivolumab in patients with advanced solid tumors stratified by tumor biomarkers
    Status Notes
    Activation: This study is reopened to accrual effective January 16th, 2024 at 12PM PST.
    Research Committee(s)
    iMATCH
    Head and Neck Cancer
    Melanoma
    Early Therapeutics & Rare Cancers
    Immunomolecular Therapeutics
    Activated
    10-14-2022
    ClinicalTrials.gov Registry Number
    NCT 05136196
    Open
    Phase
    Accrual
    8%
    SWOG Clinical Trial Number
    S2200

    S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
    Status Notes
    Active effective 09/19/2022
    Research Committee(s)
    Genitourinary Cancer
    Activated
    09-19-2022
    ClinicalTrials.gov Registry Number
    NCT05411081
    Open
    Phase
    Accrual
    81%
    SWOG Clinical Trial Number
    S2108CD

    A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice to Increase Evidence-Based Genome Informed Therapy
    Research Committee(s)
    Cancer Care Delivery
    Activated
    08-22-2022
    ClinicalTrials.gov Registry Number
    NCT # 05455606
    Closed
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S1900F

    A Randomized Phase II Study of Carboplatin and Pemetrexed with or without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)
    Status Notes
    Closed 6/27/2023
    Research Committee(s)
    LungMAP
    Activated
    07-25-2022
    Closed
    06-27-2023
    ClinicalTrials.gov Registry Number
    05364645
    Open
    Phase
    Accrual
    73%
    SWOG Clinical Trial Number
    S2107

    Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
    Status Notes
    Activation Date: 06/06/2022
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    06-06-2022
    ClinicalTrials.gov Registry Number
    NCT05308446
    Closed
    Phase
    Accrual
    17%
    SWOG Clinical Trial Number
    S1800D

    A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
    Status Notes
    S1800D is permanently closed to accrual, effective March 10, 2023. This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    LungMAP
    Lung Cancer
    Activated
    02-15-2022
    Closed
    03-10-2023
    Open
    Phase
    Accrual
    23%
    SWOG Clinical Trial Number
    S2012

    Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
    Status Notes
    Activation: Effective December 02, 2021 at 2:00 p.m. Eastern.
    Research Committee(s)
    Early Therapeutics & Rare Cancers
    Activated
    12-02-2021
    ClinicalTrials.gov Registry Number
    NCT05058651